These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1069 related articles for article (PubMed ID: 18435669)

  • 21. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study.
    Schernthaner G; Rosas-Guzmán J; Dotta F; Guerci B; Simó R; Festa A; Kiljański J; Zhou M; Gallwitz B
    Diabetes Obes Metab; 2015 Jul; 17(7):689-98. PubMed ID: 25846577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
    Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
    PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment intensification for patients with type 2 diabetes and poor glycaemic control.
    Fu AZ; Sheehan JJ
    Diabetes Obes Metab; 2016 Sep; 18(9):892-8. PubMed ID: 27160505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia.
    Fonseca V; Gill J; Zhou R; Leahy J
    Diabetes Obes Metab; 2011 Sep; 13(9):814-22. PubMed ID: 21481127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diabetes treatment intensification and associated changes in HbA1c and body mass index: a cohort study.
    Roumie CL; Greevy RA; Grijalva CG; Hung AM; Liu X; Griffin MR
    BMC Endocr Disord; 2016 Jun; 16(1):32. PubMed ID: 27255309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pre-existing cardiovascular diseases and glycemic control in patients with type 2 diabetes mellitus in Europe: a matched cohort study.
    Fu AZ; Qiu Y; Radican L; Yin DD; Mavros P
    Cardiovasc Diabetol; 2010 Apr; 9():15. PubMed ID: 20409333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17).
    Scheen AJ; Tan MH; Betteridge DJ; Birkeland K; Schmitz O; Charbonnel B;
    Diabet Med; 2009 Oct; 26(10):1033-9. PubMed ID: 19900236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thailand diabetes registry project: glycemic control in Thai type 2 diabetes and its relation to hypoglycemic agent usage.
    Kosachunhanun N; Benjasuratwong Y; Mongkolsomlit S; Rawdaree P; Plengvidhya N; Leelawatana R; Bunnag P; Pratipanawatr T; Krittiyawong S; Suwanwalaikorn S; Deerochanawong C; Chetthakul T; Ngarmukos C; Komoltri C
    J Med Assoc Thai; 2006 Aug; 89 Suppl 1():S66-71. PubMed ID: 17715836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis.
    Phung OJ; Sobieraj DM; Engel SS; Rajpathak SN
    Diabetes Obes Metab; 2014 May; 16(5):410-7. PubMed ID: 24205921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy.
    Riedel AA; Heien H; Wogen J; Plauschinat CA
    Pharmacotherapy; 2007 Aug; 27(8):1102-10. PubMed ID: 17655510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Secondary failure of glycemic control for patients adding thiazolidinedione or sulfonylurea therapy to a metformin regimen.
    Riedel AA; Heien H; Wogen J; Plauschinat CA
    Am J Manag Care; 2007 Aug; 13(8):457-63. PubMed ID: 17685826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
    Turner RC; Cull CA; Frighi V; Holman RR
    JAMA; 1999 Jun; 281(21):2005-12. PubMed ID: 10359389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcomes of initiation of therapy with once-daily combination of a thiazolidinedione and a biguanide at an early stage of type 2 diabetes.
    Bell DS; Ovalle F
    Diabetes Obes Metab; 2004 Sep; 6(5):363-6. PubMed ID: 15287929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Change in glycated haemoglobin levels after initiating second-line therapy in type 2 diabetes: a primary care database study.
    Rathmann W; Bongaerts B; Kostev K
    Diabetes Obes Metab; 2016 Aug; 18(8):840-3. PubMed ID: 27062643
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study.
    Rodríguez A; Reviriego J; Karamanos V; del Cañizo FJ; Vlachogiannis N; Drossinos V;
    Cardiovasc Diabetol; 2011 Feb; 10():18. PubMed ID: 21314919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypoglycemia Incidence Rates and Associated Health Care Costs in Patients with Type 2 Diabetes Mellitus Treated with Second-Line Linagliptin or Sulfonylurea After Metformin Monotherapy.
    Raju A; Shetty S; Cai B; D'Souza AO
    J Manag Care Spec Pharm; 2016 May; 22(5):483-92. PubMed ID: 27123911
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early glycaemic control among patients with type 2 diabetes and initial glucose-lowering treatment: a 13-year population-based cohort study.
    Thomsen RW; Baggesen LM; Svensson E; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
    Diabetes Obes Metab; 2015 Aug; 17(8):771-80. PubMed ID: 25929277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England.
    Heald AH; Fryer AA; Anderson SG; Livingston M; Lunt M; Davies M; Moreno GYC; Gadsby R; Young RJ; Stedman M
    Diabetes Obes Metab; 2018 Jul; 20(7):1659-1669. PubMed ID: 29516618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Six-month effectiveness and tolerability of pioglitazone in combination with sulfonylureas or metformin for the treatment of type 2 diabetes mellitus].
    Rodríguez A; Reviriego J; Polavieja P; Mesa J
    Med Clin (Barc); 2008 Nov; 131(19):721-30. PubMed ID: 19091199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.